Abstract

Analysis of 10 finding(s) across 2 source(s) reveals converging evidence on GLP-1 receptor agonist cardiovascular safety signals.

Key finding: Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.. Post-transplant metabolic management remains challenging, as immunosuppression ex.

Evidence spans chembl_drug_search, pubmed_search, strengthening the cross-source signal.

Evidence

pubmed_search

• Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.. Post-transplant metabolic management remains challenging, as immunosuppression exacerbates diabetes and obesity, threatening graft outcomes. While incretin-based therapies have transformed metabolic care, data on tirzepatide-a dual GIP/GLP-1 receptor agonist-in solid organ transplantation (SOT) are scarce. This review synthesizes early real-world evidence on tirzepatide's efficacy and safety in this high-risk population. A structured search of major databases identified 10 eligible reports; however, quantitative synthesis was restricted to the 6 studies (n = 182 recipients) providing disaggregated tirzepatide data. In this specific subset, tirzepatide demonstrated robust metabolic efficacy, with HbA1c reductions of 0.6-1.4 percentage points and weight loss of 5.5-6.9 kg. Crucially, renal parameters remained stable, with one study noting a modest eGFR increase (+3 mL/min/1.73 m) and another reporting significant proteinuria reduction. Tacrolimus trough levels showed minimal fluctuation (Δ -0.2 to +0.2 ng/mL), suggesting no clinically significant pharmacokinetic interaction. Adverse events were predominantly gastrointestinal and manageable, with no signals of acute rejection or graft dysfunction. Despite limitations inherent to retrospective data and small sample sizes, preliminary evidence suggests tirzepatide is a potent strategy for cardiometabolic optimization in SOT, offering significant benefits without compromising graft function. These promising signals warrant confirmation in prospective, multicenter trials to definitively establish safety and long-term outcomes. Source: pmid: 41707409, doi: 10.1016/j.trre.2026.101003
• Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study.. Incretin-based therapies are essential in diabetes management, with semaglutide receiving attention due to its oral formulation and benefits in cardiovascular health, renal function and weight loss. However, rodent studies have shown that long-term Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) exposure can induce proliferative changes, including thyroid C-cell tumors and epithelial cell hyperplasia, through GLP-1R-mediated pathways, raising concerns about potential mitogenic effects in other tissues. This study evaluates the association between semaglutide and bile duct cancer using pharmacovigilance data. A disproportionality analysis was conducted using VigiBase, the WHO's global safety database. Individual Case Safety Reports from January 1, 2009, to July 31, 2023, were analyzed, focusing on neoplasms classified under System Organ Classes. Signal detection was assessed using the lower 95% credibility interval limit for the Information Component (IC025), Proportional Reporting Ratio (PRR025) and Reporting Odds Ratio (ROR025). Patient demographics, drug dosage, treatment duration and severity of reported cases were reviewed qualitatively. Among 75,497 adverse events from 28,403 patients, 442 (0.58%) were linked to benign and malignant neoplasms. Pancreatic cancer (70 cases) was the most frequent, followed by breast (28 cases), thyroid (14 cases) and medullary thyroid cancer (15 cases). Six cases were identified in VigiBase-four as 'bile duct cancer' and two as 'cholangiocarcinoma'-potentially indicating overlapping diagnoses. Disproportionality analysis for bile duct cancer (n = 4) showed an OR of 2.30, IC of 0.23, and PRR of 2.30, exceeding thresholds for signal detection. While this study identifies a potential safety signal between semaglutide use and bile duct cancer, causality cannot be established. These findings underscore the importance of ongoing pharmacovigilance and the need for long-term observational studies and randomized controlled trials. Source: pmid: 41639322, doi: 10.1007/s12664-025-01891-4
• The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.. Recently, a large clinical trial found that treatment with semaglutide significantly reduced the risk of renal damage and cardiovascular death in patients with type 2 diabetes (T2D). To validate these findings and ensure the suitability of the drug, it is necessary to address the renal and cardiac safety of semaglutide in patients with T2D through real-world safety evidence. We examined post-marketing data on the use of semaglutide in patients with T2D using disproportionality analysis based on the FDA Adverse Event Reporting System database. We focused on the detection of positive signals for acute and chronic renal injury and cardiac adverse events associated with semaglutide therapy. A total of 2,380 patients were enrolled in semaglutide therapy in T2D patients with no renal or cardiac positive signals in four algorithmic thresholds, including disproportionality analysis. In the current study, we observed no significant cardiac or renal safety signals in patients with T2D treated with semaglutide. Our results provide further support for its use as initial and combination therapy in relevant populations. Source: pmid: 40349689, doi: 10.1159/000546238

chembl_drug_search

• MEDI-7219 — Protein
• GLP-1 — Protein
• ICANBELIMOD — Small molecule

Testable Predictions

1. Prediction: Dose-dependent toxicity is likely; lower-dose formulations may show improved therapeutic index
2. Prediction: Late-stage clinical signals suggest regulatory review may require additional safety endpoints

Limitations

• Limitation (chembl_drug_search): Data from chembl_drug_search may have unknown biases
• Limitation (pubmed_search): Publication bias may overrepresent positive findings
• Limitation: Limited source coverage reduces confidence in cross-source correlation

References

• pmid: 41707409
• doi: 10.1016/j.trre.2026.101003
• pmid: 41639322
• doi: 10.1007/s12664-025-01891-4
• pmid: 40349689
• doi: 10.1159/000546238
• pmid: 39605914
• doi: 10.3389/fphar.2024.1461398
• pmid: 39536238
• doi: 10.1056/NEJMoa2410819